CytomX Therapeutics Inc

6C1

Company Profile

  • Business description

    CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

  • Contact

    151 Oyster Point Boulevard
    Suite 400
    South San FranciscoCA94080
    USA

    T: +1 650 515-3185

    E: [email protected]

    https://www.cytomx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    121

Stocks News & Analysis

stocks

We remove our Moat Rating from ASX listed share

Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks

Best sustainable companies to own in 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks

New data centre deal for ASX listed REIT

New parternship adds to a growing data centre pipeline in fiscal 2026.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,034.702.20-0.02%
CAC 408,195.2145.710.56%
DAX 4024,539.3448.930.20%
Dow JONES (US)48,382.39319.100.66%
FTSE 1009,951.1419.760.20%
HKSE26,361.5623.090.09%
NASDAQ23,235.636.36-0.03%
Nikkei 22551,832.801,493.322.97%
NZX 50 Index13,587.2338.810.29%
S&P 5006,858.4712.970.19%
S&P/ASX 2008,728.602.600.03%
SSE Composite Index4,022.6053.761.35%

Market Movers